Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

iBio, Inc. (IBIO)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.8045+0.0042 (+0.52%)
At close: 4:00PM EDT
0.8124 +0.01 (+0.98%)
After hours: 05:08PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.8003
Open0.7753
Bid0.8041 x 800
Ask0.8042 x 800
Day's Range0.7753 - 0.8197
52 Week Range0.7753 - 2.8300
Volume2,400,790
Avg. Volume2,929,904
Market Cap175.279M
Beta (5Y Monthly)-5.94
PE Ratio (TTM)N/A
EPS (TTM)-0.1200
Earnings DateNov 15, 2021 - Nov 19, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for IBIO

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • iBio, Inc.
    The Argus Innovation Model PortfolioThe United States economy is full of innovation. It has to be. Manufacturing industries that dominated the economy decades ago - textiles, televisions, even automobiles to a large degree - have moved overseas, where costs are lower. Yet the U.S. economy, even during the pandemic, has expanded to record levels. If U.S. corporations weren't innovating, the domestic economy would not be growing and capital would not be flooding into the country. Consider that U.S. GDP was approximately $1 trillion in 1930 but nearly $23 trillion at the end of 1H21. That's growth of 23-times. Meanwhile, the U.S. population has grown less than three-times during that time span, to 320 million from 120 million. The delta between GDP growth and population growth has been driven, in large part, by innovation. In addition, the value of listed corporations on U.S. stock exchanges at the end of 2020 was approximately $41 trillion, according to SIFMA, representing 38% of global equity market capitalization, while U.S. GDP represented only 26% of global GDP. The current low level of interest rates and the relatively high level of the dollar both attest to the confidence that global investors have in the innovative U.S. economy.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • Motley Fool

    This Under-the-Radar Pharma Company Could Be a Bargain Hunter's Dream

    Companies touting successful treatment candidates to fight COVID-19 are in the healthcare spotlight, gaining the attention of investors. This includes biotech companies such as iBio (NYSEMKT: IBIO), an innovator specializing in the manufacturing and production of antibodies and vaccines under development. Now, a brief renewed interest from investors is the result of exclusive licensing deals and positive pre-clinical studies involving its most promising candidates.

  • GlobeNewswire

    iBio Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Corporate Update

    Expanded Immuno-Oncology Pipeline with License of Next-Gen anti-CD25 Antibody for Solid Tumors Paired Access to RubrYc’s Antibody Discovery Platform with FastPharming® and GlycaneeringTM Platforms to Accelerate Drug Development Advanced COVID-19 Nucleocapsid-based Vaccine Candidate with pre-IND Submission BRYAN, Texas, Sept. 27, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based

  • GlobeNewswire

    iBio to Participate in the Cantor 2021 Virtual Global Healthcare Conference

    BRYAN, Texas, Sept. 20, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, today announced that the Company’s Chairman & CEO, Tom Isett, and its CSO, Martin Brenner, DVM, Ph.D., will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 10:00 a.m. Eastern Time. The fireside chat will

Advertisement
Advertisement